The government promulgated the revised Pharmacist Act today (20th), which includes restrictions on co-living and clinical 1+3 of generic and new drugs and mandatory preparation of CSO expenditure reports.

In accordance with the revised Pharmaceutical Law, restrictions on 1+3 generic and improvement new drugs and regulations requiring CSOs to be included in the scope of pharmaceutical suppliers and to prepare expenditure reports will be enforced immediately after promulgation.

Dailypharm summarized the details and timing of implementation of the revised Pharmacist Act.

◆Limitation of 1+3 on generic and improvement new drugs ◆
The regulation shall be impleme